Align Technology (ALGN)
(Delayed Data from NSDQ)
$219.70 USD
+3.68 (1.70%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $219.71 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$219.70 USD
+3.68 (1.70%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $219.71 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Zacks News
Genomic Health (GHDX) Oncotype DX Score Test Data Positive
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.
Boston Scientific Receives FDA Nod for Vercise DBS System
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
by Zacks Equity Research
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife
by Zacks Equity Research
Hill-Rom's (HRC) upbeat long-term view buoys optimism.
Inogen Rides on Solid Product Portfolio Amid Forex Woes
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.
Omnicell's Rising Costs Affect Bottom Line Amid Competition
by Zacks Equity Research
Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.
Myriad Genetics Presents Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.
NxStage Nx2me Connected Health Improves Home Hemodialysis
by Zacks Equity Research
NxStage Medical (NXTM) consistently looks to expand dialysis platform.
Buy These 4 Stocks With Excellent Earnings Growth
by Tirthankar Chakraborty
We have picked stocks that have displayed historical earnings growth and are also seeing a rise in quarterly and annual earnings estimates.
Varian Halcyon Gets ANVISA Registration, Grows in Oncology
by Zacks Equity Research
Varian (VAR) consistently tries to expand in the global market with Halcyon system.
Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus
by Zacks Equity Research
Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.
Myriad Genetics (MYGN) Presents Positive riskScore Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod
by Zacks Equity Research
Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.
Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival
by Zacks Equity Research
Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.
Walgreens Boots Invests in China to Fortify Retail Pharmacy
by Zacks Equity Research
Walgreens Boots' (WBA) decision to buy a minority stake in Sinopharm Holding Guoda Drugstores is likely to leverage its global pharmacy expertise.
Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio
by Zacks Equity Research
Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.
Hologic Banks on Molecular Diagnostics, Competition Rife
by Zacks Equity Research
Hologic (HOLX) gains on increasing market share and utilization of fully-automated Panther system.
Here's Why You Should Invest in PetMed (PETS) Stock Now
by Zacks Equity Research
PetMed's (PETS) implements strategies to revitalize top line. It also offers a comprehensive portfolio.
IDEXX Laboratories Banks on Global Prospects, CAG Strength
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides on strength across all segments, especially CAG. Strong fundamentals buoy optimism.
Align Technology Rides High on InvisAlign & Strategic Pacts
by Zacks Equity Research
Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).
CVS-Aetna Deal: What's Hot, What's Not
by Zacks Equity Research
CVS Health (CVS) and Aetna consolidation to add a new dimension to healthcare landscape. However, critics believe the gain will be short-lived for the healthcare society.
The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics
Quest Diagnostics Banks on Buyouts to Expand in Diagnostic
by Zacks Equity Research
Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.
Patterson Companies-SprintRay Deal to Boost Dental Unit
by Zacks Equity Research
Patterson Companies (PDCO) focuses on acquisitions to boost dental segment.
Why Align Technology (ALGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Align Technology (ALGN) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.